Accueil / Les équipes / VIH, hépatites virales et comorbidités : épidémiologie clinique et santé publique – MORPH3Eus
Objectifs
The team will focus on three research axes using a multidisciplinary translational approach involving epidemiologists, biostatisticians, clinicians, immunologists, and health economists, and major research tools and platforms, i.e cohorts (ANRS CO3 Aquitaine, ANRS CO13 HEPAVIH, ANRS CO5 HIV-2), collaboration of European cohorts (COHERE, EuroCoord, ACHIEV2E), and clinical trials, all coordinated in our ISO certified clinical trial unit.
Axes
- Nowadays, HIV-infected patients are mainly experiencing non-AIDS comorbidities such as malignancies, liver diseases, neurocognitive disorders, atherothrombosis and cardiovascular events, renal failure or osteoporosis in the context of widespread use of combination antiretroviral therapy. We will study the long term impact of HIV infection and durability of the impact of related long term treatment regarding the burden of multimorbidity in ageing HIV-1 and HIV-2 infected patients.
- The introduction of direct-acting antivirals (DAAs) for HCV has resulted in much higher sustained virological rates and lower side effects have been observed. Next generation DAAs are more promising and may offer the potential for a cure in the large majority of HCV mono-infected patients. However, data for HIV/HCV co-infected patients are still scarce and a large-scale assessment of these drugs is lacking. We will investigate questions regarding treatment response, tolerability, drug-drug interactions, resistance, and effect on related co-morbidities in HIV/HCV co-infected patients. One major objective will be to study the effect and the tolerance of DAAs recently introduced in the routine care in HCV/HIV co-infected patients.
- An estimated 80 000 HIV-infected patients are under medical care in France. The annual overall cost for the French public health system is 1.5 billion euros (including 1 billion for antiretroviral therapy). Therefore, we aim at analyzing the consumption of care according to different profiles of patients, depending on their immuno-virological status and the presence/absence of co-morbidities including co-infection with hepatitis B or C viruses. Data of the Aquitaine region (5000 HIV-infected patients), in 2013 then every two years, will be used.
Principales publications
- Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G; EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011 May;11(5):363-71.
- Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009 Nov 1;49(9):1441-9.
- Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P, Mortalité Study Group. Changes in cancer mortality among HIV-infected patients: The ANRS Mortalité 2005 survey. Clin Infect Dis 2009;48(5):633-639
- Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d’Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G on behalf of COHERE, The Collaboration of Observational HIV Epidemiological Research Europe in EuroCoord. All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012;41(2):433-4455.
- Bruyand M, Thiébaut R, Lawson-Ayayi S, Joly P, Sasco AJ, Mercié P, Pellegrin JL, Neau D, Dabis F, Morlat P, Chêne G, Bonnet F; Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009 Oct 1;49(7):1109-16.
Coordonnées
Centre de recherche INSERM U1219
Université de Bordeaux – ISPED Case 11
146 rue Léo-Saignat
33076 BORDEAUX cedex
Tél : +33 (0)5 57 57 45 40
Tél : +33 (0)5 57 57 13 92
- Directrice :
MD PhD HDRResponsable de l’équipe VIH, Hépatites virales et co-morbidités: épidémiologie clinique et santé publique / Head of team Multimorbidity and Public Health in Patients with HIV or HepatitisResponsable du CMG-EC Inserm-ANRS/ Head of clinical trial unit Inserm-ANRSParcours
2015 Habilitation, Ecole Doctorale Scoiétés, Politique, Santé Publique, Speciality: Public Health, University of Bordeaux, France 2010 PhD in Science, Technology and Health, Speciality: Epidemiology and Public Health, University of Bordeaux, Bordeaux, France. 2007 MD, Justus Liebig University, Giessen, Germany. 2007 MSc in Epidemiology and Biostatics, University of Bordeaux, ISPED, Bordeaux, France. 2004 Approbation – German official license to practice as a doctor, Federal State examination board for therapeutic professions – Hessisches Landesprüfungsamt für Heilberufe, Frankfurt am Main, Hessen, Germany. 2003 Certificate of the Medical Examination, Federal State examination board for therapeutic professions – Hessisches Landesprüfungsamt für Heilberufe, Frankfurt am Main, Hessen, Germany. 1997-2003 Medical School, Justus Liebig University, Giessen, Germany and Universidad Autonoma, Madrid, Spain. - Contacts : Audrey Legrand – Emilie Boschet
Informations
Warning: array_merge(): Argument #2 is not an array in /home/insermu897/public_html/wp-content/themes/bphcenter/single.php on line 307
Membres
- Florence Allais
- Diana Barger
Doctorante – PhD CandidateCoordinateur d’étude – Study CoordinatorDiana Barger is currently a PhD candidate (thèse de sciences) in public health specialising in epidemiology at the University of Bordeaux’s Institute of Public Health, Epidemiology and Development (ISPED).
Her doctoral research is being supervised by Professors Fabrice Bonnet and François Dabis within the Inserm Bordeaux Population Health Centre (U-1219). It focusses on developing and deploying new technology to better collect patient-reported outcomes (PRO), including quality of life, in patients in long-term, hospital-based, HIV care. By identifying risk profiles for those with poorer quality of life, this work ultimately aims to inform and improve care for those aging with HIV. She was awarded a grant in 2016 from the French NGO Sidaction to carry out this work. This research has also been granted seed funding from the ANRS (French REcherche Nord & sud Sida-HIV Hépatites). Diana holds an MPH (Masters in Public Health) from the London School of Hygiene and Tropical Medicine (2012) and a BA with Magna Cum Laude honors in political science from Tufts University (2008).
Previously, Diana worked as an International Project Coordinator supporting the FP-7 funded European collaboration of cohorts of people living with HIV, COHERE in EuroCoord between 2013-2015. She has also served at both Save the Children International and the United Nations Population Fund as an independent consultant. She has experience conducting economic evaluations and M&E as well as specific expertise in the field of sexual and reproductive health.
She is interested in the development, validation and deployment patient-reported outcomes (both in controlled and routine settings), health services and health evaluation and outcomes research.
- Christine Betard
- Emilie Boschet
- Celine Colin
- Laure Esterle Project Manager, team ANRS CO13 Hepavih
Parcours
Education / Training
2009 PhD thesis, Université Paris Descartes (Paris 5)2005 Master 2 of Biology & Health (Food Science and Nutrition), Université Bordeaux 1/2 - Camille Gilbert
- Stephanie Gillet
- Lucile Hardel
- Delphine Jean
- Fabien Le Marec
- Laurence Merchadou
- Loretxu Pinoges
- Elodie Rouch
- AnneAygline Soutthiphong
- Cedrick Wallet
- Linda Wittkop MD PhD HDRResponsable de l’équipe VIH, Hépatites virales et co-morbidités: épidémiologie clinique et santé publique / Head of team Multimorbidity and Public Health in Patients with HIV or HepatitisResponsable du CMG-EC Inserm-ANRS/ Head of clinical trial unit Inserm-ANRS
Parcours
2015 Habilitation, Ecole Doctorale Scoiétés, Politique, Santé Publique, Speciality: Public Health, University of Bordeaux, France 2010 PhD in Science, Technology and Health, Speciality: Epidemiology and Public Health, University of Bordeaux, Bordeaux, France. 2007 MD, Justus Liebig University, Giessen, Germany. 2007 MSc in Epidemiology and Biostatics, University of Bordeaux, ISPED, Bordeaux, France. 2004 Approbation – German official license to practice as a doctor, Federal State examination board for therapeutic professions – Hessisches Landesprüfungsamt für Heilberufe, Frankfurt am Main, Hessen, Germany. 2003 Certificate of the Medical Examination, Federal State examination board for therapeutic professions – Hessisches Landesprüfungsamt für Heilberufe, Frankfurt am Main, Hessen, Germany. 1997-2003 Medical School, Justus Liebig University, Giessen, Germany and Universidad Autonoma, Madrid, Spain.
